AEVASI (Spain) AIVA Italy APACS (Italy) Association Takayasu France ATAK (Takayasu Spain) ELEANA (Greece) France Vascularites Kosapo (Japan) SHG Mainz (Germany) SHG Frankfurt (Germany) SHG Nordbayern (Germany) SHG Sachsen (Germany) VASAS (Switzerland) Vasculitis Awareness Ireland Vasculitis Foundation (USA) Vasculitis Foundation (Canada) Vasculitis (Poland) Vasculitis Society (India) Vasculitis Stichting (Netherlands) Vasculitis UK (United Kingdom) Vaskuliittiyhdistys (Finland) Vaskulitida.cz (Czech Republik)
The latest news......
A new study medicine for kidney vasculitis
On 5 October 2026, CSL and the Swiss company Alentis Therapeutics announced a global partnership to develop lixudebart. This study medicine is aimed at AAV with rapidly progressive glomerulonephritis (AAV-RPGN), the form in which kidney function can decline within days or weeks.
Reducing steroids in GPA and MPA: what is in development?
Since avacopan was taken off the European market, many patients with GPA or MPA ask: is anyone else working on medicines that could reduce our use of corticosteroids such as prednisolone? The answer is yes, but it will likely take several years before they reach patients.
EGPA meeting in Milan on 7 November
On 7 November 2026, the Italian patient association APACS will bring people living with EGPA, their families and clinicians together in Milan for a day of learning and open discussion.
patients
Find Patient Advocacy Groups (VPAGs)
hospitals
Find vasculitis expertise
projects
Find out about the projects we are working on.